SCHEMBL731212

SCHEMBL731212

C1CN(CC2CC2)[12CH2]CN1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.48
ADRA2C P18825 1/20 0.48
ACHE P22303 1/20 0.41
GBA1 P04062 2/20 0.40
RAD52 P43351 1/20 0.39
CNR1 P21554 1/20 0.39
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CACNA2D1 P54289 1/20 0.37
CACNA1B Q00975 1/20 0.37
CACNB1 Q02641 1/20 0.37
SIGMAR1 Q99720 3/20 0.37
CXCR4 P61073 2/20 0.37
CHRM3 P20309 1/20 0.36
SCN1A P35498 1/20 0.35
SCN4A P35499 1/20 0.35
SCN7A Q01118 1/20 0.35
KCNH2 Q12809 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912326 1.00 CHRM5 (0.48) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL20873850 1.00 CHRM5 (0.48) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL92626 1.00 CHRM5 (0.48) CHRM5ADRA2CACHEGBA1RAD52
Bromide SCHEMBL31114948 0.97 CHRM5 (0.46) CHRM5ADRA2CACHEGBA1RAD52
Hydrochloric Acid SCHEMBL21001940 0.97 CHRM5 (0.46) CHRM5ADRA2CACHEGBA1RAD52
Hydrochloric Acid SCHEMBL4668199 0.97 CHRM5 (0.46) CHRM5ADRA2CACHEGBA1RAD52
Hydrochloric Acid SCHEMBL5570644 0.97 CHRM5 (0.46) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL2570307 0.92 GBA1 (0.47) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL1268833 0.91 ADRA2C (0.52) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL211956 0.90 CHRM5 (0.56) CHRM5ADRA2CACHEGBA1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3098223-A1 CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE Boehringer Ingelheim International GmbH (DE) 2016-11-30 EP disclosed
US-8664222-B2 Specific salt, anhydrous and crystalline form of a dihydropteridione derivative BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-03-04 US disclosed
EP-1778668-B1 METHOD FOR THE PRODUCTION OF DIHYDROPTERIDINONES BOEHRINGER INGELHEIM INT (DE) 2013-07-03 EP disclosed
EP-2543669-A2 Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation Boehringer Ingelheim International GmbH (DE) 2013-01-09 EP disclosed
US-8329695-B2 Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-11 US disclosed
US-20120214995-A1 SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
US-8188086-B2 Specific salt, anhydrous and crystalline form of a dihydropteridione derivative BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-29 US disclosed
US-8138341-B2 Intermediate compounds useful for the manufacture of dihydropteridinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-20 US disclosed
US-8138373-B2 Process for the manufacture of dihydropteridinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-20 US disclosed
US-20100280037-A1 CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
EP-2185559-A1 CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE Boehringer Ingelheim International GmbH (DE) 2010-05-19 EP disclosed
WO-2009019205-A1 CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-12 WO disclosed
US-20090030004-A1 SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE ONCOHEROES BIOSCIENCES INC. 2009-01-29 US disclosed
EP-1984367-A1 TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-29 EP disclosed
US-7439358-B2 Specific salt, anhydrous and crystalline form of a dihydropteridione derivative BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-21 US disclosed
US-20080177066-A1 Process for the manufacture of dihydropteridinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-24 US disclosed
US-20070203146-A1 N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide ONCOHEROES BIOSCIENCES INC. 2007-08-30 US disclosed
WO-2007090844-A1 TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 WO disclosed
EP-1778668-A2 METHOD FOR THE PRODUCTION OF DIHYDROPTERIDINONES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-02 EP disclosed
WO-2006018220-A2 METHOD FOR THE PRODUCTION OF DIHYDROPTERIDINONES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214995-A1 SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE QDPR, REN, DHPS CHRM5 2784/4885ADRA2C 1117/4885ACHE 4141/4885
US-20100280037-A1 CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE QDPR, DHPS, DPYD CHRM5 2345/4885ADRA2C 1537/4885ACHE 3863/4885
US-20070203146-A1 N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide DHPS, PKD1, AQP4 CHRM5 2212/4885ADRA2C 1300/4885ACHE 4143/4885
US-20080177066-A1 Process for the manufacture of dihydropteridinones QDPR, DHPS, DHODH CHRM5 2560/4885ADRA2C 2492/4885ACHE 3463/4885
US-20090030004-A1 SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE QDPR, REN, DHPS CHRM5 2784/4885ADRA2C 1117/4885ACHE 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.